Beijing Amet's high-pressure balloon dilatation catheter product was successfully approved for launch

Release time:

2021-07-16 09:10

Source:

On May 21, 2021, Beijing Amet Medical Devices Co., Ltd. obtained the medical device registration certificate for "High Pressure Balloon Dilation Catheter" issued by the State Drug Administration (Registration Certificate No.: National Instruments Note 20213030338), July 2 It obtained the medical device production license issued by the Beijing Municipal Drug Administration.

　　

image.png

 

This high-pressure balloon dilatation catheter from Beijing Amet is suitable for dilating coronary stenotic lesions or bypass stenotic lesions to improve myocardial blood supply; it is suitable for post-implantation expansion of coronary stents. It has excellent product properties, including: excellent shape retention ability under high pressure; excellent "wing" embracing performance, which is conducive to product retraction and secondary entry into the guide tube; hydrophilic coating for durable lubrication effect , can withstand up to 25 rubs. In addition, the product has complete specifications and models and a wide coverage, which can fully meet different clinical needs.

The successful listing of Beijing Amet's high-pressure balloon dilatation catheter products fully reflects the company's level in the research and development of Class III sterile interventional medical device products and the construction of quality management systems. In the future, Amet will continue to adhere to the concept of "quality is the life of the company, innovation is the driving force of development", and provide more high-quality and innovative implantation and interventional medical devices for more patients and doctors.

Previous Page

Two invention patent applications of Beijing Amet were authorized by the State Intellectual Property Office

The randomized controlled trial of 3D printing fully degradable coronary drug-eluting stent system, an innovative device independently developed by Beijing Amet, successfully completed the enrollment of the first three subjects

Next Page

Previous Page

Two invention patent applications of Beijing Amet were authorized by the State Intellectual Property Office

Next Page

The randomized controlled trial of 3D printing fully degradable coronary drug-eluting stent system, an innovative device independently developed by Beijing Amet, successfully completed the enrollment of the first three subjects

Company Information

Beijing Advanced Medical Technologies, Inc.

Contact Us

Address: Building 11, Zhongguancun Medical Equipment Park, No. 26, Yongwang West Road, Daxing District, Beijing

Tel：010-6297-7955           E-Mail：amt@ametcorp.com

Picture Name

WeChat Contact

@Copyright 2022 Beijing Advanced Medical Technologies, Inc. All rights reserved

京ICP备11028039号   Powered by: www.300.cn   SEO